Newly Formed Clinical Advisory Board United in Potential of SAT-3247 for Duchenne Muscular Dystrophy

Published Date: 16 Jun 2024

Satellos Bioscience has established a clinical advisory board to aid in developing their lead drug candidate SAT-3247, an oral small molecule therapy for Duchenne muscular dystrophy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Reducing social media to an hour a day boosts young people's self-image.

2.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

3.

The pandemic had little impact on mental health symptoms.

4.

FDA Approves New Bladder Cancer First-Line Standard of Care.

5.

A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot